Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Mar 25;14(3):e077193. doi: 10.1136/bmjopen-2023-077193

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

RoadMAB precision dosing platform. The RoadMAB New Start Wizard will launch prior to the first dose. Pretreatment biomarkers, including weight, albumin, erythrocyte sedimentation rate and neutrophil CD64, are manually entered into the table prior to launching the platform. The Wizard uses dynamic disease progression modelling along with the population pharmacokinetic model to simulate a dosing regimen to achieve the (A) dose 3 (week 6) target concentration of 18–24 µg/mL. The default tab is (B) model-informed dosing, however, the user can also toggle through (C) standard dosing and (D) manual dosing to inform the dosing decision. (E) The predicted concentration over time curve is shown and based on the selected starting dose.